These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22910338)

  • 1. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.
    Zugna D; Geskus RB; De Stavola B; Rosinska M; Bartmeyer B; Boufassa F; Chaix ML; Babiker A; Porter K;
    Antivir Ther; 2012; 17(6):1039-48. PubMed ID: 22910338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.
    Lodi S; Phillips A; Fidler S; Hawkins D; Gilson R; McLean K; Fisher M; Post F; Johnson AM; Walker-Nthenda L; Dunn D; Porter K;
    PLoS One; 2013; 8(9):e75608. PubMed ID: 24086588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.
    Lodi S; Meyer L; Kelleher AD; Rosinska M; Ghosn J; Sannes M; Porter K
    Arch Intern Med; 2012 Sep; 172(16):1252-5. PubMed ID: 22826124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
    Ngo-Giang-Huong N; Wittkop L; Judd A; Reiss P; Goetghebuer T; Duiculescu D; Noguera-Julian A; Marczynska M; Giacquinto C; Ene L; Ramos JT; Cellerai C; Klimkait T; Brichard B; Valerius N; Sabin C; Teira R; Obel N; Stephan C; de Wit S; Thorne C; Gibb D; Schwimmer C; Campbell MA; Pillay D; Lallemant M;
    BMC Infect Dis; 2016 Nov; 16(1):654. PubMed ID: 27825316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.
    Wyl Vv; Gianella S; Fischer M; Niederoest B; Kuster H; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
    PLoS One; 2011; 6(11):e27463. PubMed ID: 22102898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study.
    Pérez-Molina JA; Mora Rillo M; Suárez-Lozano I; Casado-Osorio JL; Teira Cobo R; Rivas González P; Pedrol Clotet E; Hernando-Jerez A; Domingo P; Barquilla Díaz E; Esteban H; González-García J;
    HIV Clin Trials; 2012; 13(3):131-41. PubMed ID: 22592093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort.
    Nozza S; Cozzi-Lepri A; Bai F; Rusconi S; Gori A; Cinque P; Ammassari A; Caramello P; Tambussi G; D'Arminio Monforte A; Marchetti G;
    PLoS One; 2017; 12(12):e0189045. PubMed ID: 29206853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion.
    Thiébaut R; Jacqmin-Gadda H; Walker S; Sabin C; Prins M; Del Amo J; Porter K; Dabis F; Chêne G;
    HIV Med; 2006 Jan; 7(1):1-9. PubMed ID: 16313286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antiretroviral treatment of different durations in primary HIV infection.
    Pantazis N; Touloumi G; Vanhems P; Gill J; Bucher HC; Porter K;
    AIDS; 2008 Nov; 22(18):2441-50. PubMed ID: 19005267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.
    Samji H; Taha TE; Moore D; Burchell AN; Cescon A; Cooper C; Raboud JM; Klein MB; Loutfy MR; Machouf N; Tsoukas CM; Montaner JS; Hogg RS;
    HIV Med; 2015 Feb; 16(2):76-87. PubMed ID: 25174373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.
    Hughes RA; Sterne JA; Walsh J; Bansi L; Gilson R; Orkin C; Hill T; Ainsworth J; Anderson J; Gompels M; Dunn D; Johnson MA; Phillips AN; Pillay D; Leen C; Easterbrook P; Gazzard B; Fisher M; Sabin CA
    HIV Med; 2011 Nov; 12(10):583-93. PubMed ID: 21569188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.
    Pantazis N; Touloumi G; Meyer L; Olson A; Costagliola D; Kelleher AD; Lutsar I; Chaix ML; Fisher M; Moreno S; Porter K;
    AIDS; 2016 Mar; 30(6):879-88. PubMed ID: 26636925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
    Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort.
    Koegl C; Wolf E; Hanhoff N; Jessen H; Schewe K; Rausch M; Goelz J; Goetzenich A; Knechten H; Jaeger H; Becker W; Becker-Boost I; Berzow D; Beiniek B; Brust J; Shcuster D; Dupke S; Fenske S; Gellermann HJ; Gippert R; Hartmann P; Hintsche B; Jaeger H; Jaegel-Guedes E; Jessen H; Gölz J; Koelzsch J; Helm EB; Knecht G; Knechten H; Lochet I; Gute P; Mauruschat S; Mauss S; Miasnikov V; Mosthaf FA; Rausch M; Freiwald M; Reuter B; Schalk HM; Schappert B; Schnaitmann E; Schneider I; Schüler-Maué W; Schuler C; Seidel T; Starke W; Ulmer A; Müller M; Weitner I; Schewe K; Zamani C; Hanmond A; Ross K; Bottlaender A; Hoffmann C; Dix A; Schneidewind A; Lademann M;
    Eur J Med Res; 2009 Jul; 14(7):277-83. PubMed ID: 19661009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
    ; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
    AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.